-
Innovation Ranking
NewInnovation Ranking – Viridian Therapeutics Inc
Viridian Therapeutics Inc (Viridian), formerly Miragen Therapeutics Inc is a clinical stage biopharmaceutical company. The company discovers and develops novel RNA-based therapeutics, with a core focus on therapeutic antibodies and their roles in diseases. It focuses on thyroid eye disease and cardiovascular disease areas. Viridian lead pipeline products candidates include VRDN-001 (Intravenous) for treating thyroid eye disease (TED); and VRDN-002 (Subcutaneous), an inhibitor using half-life technology for treating thyroid eye disease (TED). The company has been depending on the third...
-
Product Insights
NewNet Present Value Model: Viridian Therapeutics Inc’s VRDN-001
Empower your strategies with our Net Present Value Model: Viridian Therapeutics Inc's VRDN-001 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AVE-1642 in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AVE-1642 in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AVE-1642 in Graves' Ophthalmopathy Drug Details: AVE-1642 is under development for Grave's...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VRDN-002 in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VRDN-002 in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VRDN-002 in Graves' Ophthalmopathy Drug Details: VRDN-002 is under development for the...
-
Product Insights
Interstitial Lung Fibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Interstitial Lung Fibrosis - Drugs In Development, 2023’, provides an overview of the Interstitial Lung Fibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Graves’ Ophthalmopathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Graves' Ophthalmopathy - Drugs In Development, 2023’, provides an overview of the Graves' Ophthalmopathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Injectable Drug Delivery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Injectable Drug Delivery Pipeline Market Report Overview Injectable drug delivery devices help administer a drug into a patient’s blood. The Injectable Drug Delivery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials. Key Segments ·       Sustained Release Injectable...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VRDN-003 in Graves’ Ophthalmopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VRDN-003 in Graves' Ophthalmopathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VRDN-003 in Graves' Ophthalmopathy Drug Details: VRDN-003 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – DN-1508052 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - DN-1508052 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. DN-1508052 in Triple-Negative Breast Cancer (TNBC) Drug Details: DN-1508052...